What is 18F-MFBG studying for pheochromocytoma?

18F-MFBG is being studied to see how well it can detect pheochromocytoma tumors using PET imaging. Researchers want to understand if this new imaging tracer can provide clearer and faster diagnosis compared to current methods. The study is sponsored by the First Affiliated Hospital of Zhejiang University.

Who may be eligible for this pheochromocytoma clinical trial?

Adults aged 30 to 80 years with a clinical diagnosis of pheochromocytoma may be eligible. Participants must have a regular caregiver and be able to understand and follow study requirements. People with serious organ diseases or uncontrolled high blood pressure may not qualify. Please review eligibility criteria for more details.

Is there any cost to participate in this pheochromocytoma clinical trial?

Study-related care, including the imaging procedure and all trial visits, is provided at no cost. However, personal travel or other expenses related to participation may vary and are not guaranteed to be covered.

Actively Recruiting

Age: 18Years - 80Years

All Genders

ID06813742

A Prospective Exploratory Study Evaluating the Diagnostic Usefulness of 18F-mFBG PET Imaging in Pheochromocytoma

Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-07

Participants Needed

Research Sites

51 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to evaluate how well 18F-metafluorobenzylguanidine 18F-MFBG PET imaging detects and measures tumor burden in patients with pheochromocytoma, a type of tumor that highly expresses the norepinephrine transporter NET. The study addresses limitations of current imaging methods, such as low resolution and long procedure times, by assessing a newer tracer that may provide better image quality and faster results. Patients with suspected or confirmed pheochromocytoma will receive a single intravenous injection of 18F-MFBG at a dose of 5.55 MBqkg. After 60 minutes, participants will undergo a PETCT or PETMR scan to visualize the tumors. This imaging method allows for scanning shortly after injection without special preparation, potentially improving diagnostic processes. During the study, researchers will evaluate the safety of 18F-MFBG, the quality of the images, and how accurately the scans correspond to pathological diagnosis and treatment effects. They will monitor false positive and false negative results over about one year. Participants will be assessed through imaging and clinical follow-up, contributing to understanding the tracers diagnostic value in pheochromocytoma.

CONDITIONS

Brief Title

18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma

Who Can Participate

Age: 18Years - 80Years

All Genders

Eligibility Criteria

You may qualify if you...

Aged 30 to 80 years old, with at least primary school education and a regular caregiver
Clinically diagnosed with pheochromocytoma
Able to provide informed consent and comply with study requirements

You will not qualify if you...

Serious diseases affecting heart, brain, liver, kidney, or blood system
Uncontrolled high blood pressure (systolic > 180 mmHg or diastolic > 110 mmHg)
Mental or primary affective disorders
Unable to understand or follow the study protocol or provide consent
Contraindications to PET imaging, including pregnancy, breastfeeding, or plans for pregnancy
Allergy to imaging agents
Inability to cooperate with PET scanning due to conditions like hypoglycemia, severe pain, or tremors

Research Team

Peipei Wang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here